# Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors

> **NCT00747474** · PHASE1 · COMPLETED · sponsor: **Taiwan Liposome Company** · enrollment: 54 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Lipotecan

## Key facts

- **NCT ID:** NCT00747474
- **Lead sponsor:** Taiwan Liposome Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-08
- **Final completion:** 2011-12
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00747474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00747474, "Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00747474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*